Rapid Innovation is Reshaping Oncology: Stocks in Focus

Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.

Zacks Investment Research • Feb 5, 2026

Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in Arcus Biosciences (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Feb 4, 2026

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 16,650 shares of the Company's common stock at an exercise price per share of $22.13, which was.

Business Wire • Jan 26, 2026

Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today outlined its 2026 priorities for casdatifan and its emerging inflammation and immunology (I&I) programs. “As we enter 2026, the highest priorities for Arcus will be the rapid enrollment of PEAK-1, our Phase 3 study evaluating casdatifan in immunotherapy.

Business Wire • Jan 7, 2026

Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return

82,997 shares were sold indirectly on Dec. 4, 2025, for a transaction value of ~$2.1 million based on a weighted average sale price of $24.71 per share. The sale represented 5.91% of total holdings, leaving the insider with 367,220 direct shares and 954,063 shares held via trust.

The Motley Fool • Jan 6, 2026

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Wednesday, January 14th, 2026, at 3:00 pm PT. A live.

Business Wire • Dec 18, 2025

Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221

RCUS is now resetting its strategy after its Phase 3 STAR-221 was discontinued. This removes domvanalimab for upper-GI cancers as a key catalyst. Instead, they'll focus now on Casdatifan (AB521), which is a wholly owned oral HIF-2α inhibitor. In my view, this makes Casdatifan the core bull thesis, especially with the Phase 3 PEAK-1 results going forward.

Seeking Alpha • Dec 17, 2025

RCUS Stock Down on Decision to Discontinue GILD Partnered Study

Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.

Zacks Investment Research • Dec 15, 2025

Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.

Investors Business Daily • Dec 12, 2025